FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987006639> ?p ?o ?g. }

• W1987006639 endingPage "333.e1" @default.
• W1987006639 startingPage "327" @default.
• W1987006639 abstract "Background & AimsInterleukin (IL)-28B (interferon-λ 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy. However, patients with HCV infection often have physical or mental comorbidities that contraindicate or complicate treatment, regardless of their genotype. The potential role of IL28B genotype within the context of patients' clinical and social environment is therefore unclear.MethodsWe characterized the IL28B genotype (for rs12980275 and rs8099917) in 308 patients (mean age, 56 y; 25% African American; 38% with advanced-stage fibrosis) with genotype 1 HCV infection seen at the Michael E. DeBakey Veterans Administration Medical Center in Houston, Texas, from May 1, 2009, through April 1, 2012. We evaluated their eligibility for antiviral treatment based on clinical and social factors such as physical or mental health comorbidity, ongoing alcohol or drug use, and noncompliance with treatment evaluation.ResultsOf the 308 subjects, 40% were homozygous for rs12980275 (associated with response to therapy), 46% were heterozygous, and 15% were homozygous for alleles associated with reduced response to therapy. Overall, 36% of patients were considered to be ineligible for treatment; of these, 40% had the rs12980275 genotype. More than half of the patients with rs12980275 who were ineligible for treatment were excluded because of mental health comorbidities; one-third of these patients had advanced fibrosis. The reason(s) for treatment exclusion resolved in only 8% of patients during a mean 1.5 years of follow-up evaluation.ConclusionsIn a well-characterized cohort of patients with HCV, a large proportion (40%) with IL28B polymorphisms associated with response to therapy is ineligible for treatment because of contraindications. One potential role of IL28B genotype analysis could be to identify patients who, although not currently eligible for antiviral treatment, could become so by modifying fixable exclusions to treatment. Interleukin (IL)-28B (interferon-λ 3) genotype is the strongest predictor of response of patients with hepatitis C virus (HCV) infection to antiviral therapy. However, patients with HCV infection often have physical or mental comorbidities that contraindicate or complicate treatment, regardless of their genotype. The potential role of IL28B genotype within the context of patients' clinical and social environment is therefore unclear. We characterized the IL28B genotype (for rs12980275 and rs8099917) in 308 patients (mean age, 56 y; 25% African American; 38% with advanced-stage fibrosis) with genotype 1 HCV infection seen at the Michael E. DeBakey Veterans Administration Medical Center in Houston, Texas, from May 1, 2009, through April 1, 2012. We evaluated their eligibility for antiviral treatment based on clinical and social factors such as physical or mental health comorbidity, ongoing alcohol or drug use, and noncompliance with treatment evaluation. Of the 308 subjects, 40% were homozygous for rs12980275 (associated with response to therapy), 46% were heterozygous, and 15% were homozygous for alleles associated with reduced response to therapy. Overall, 36% of patients were considered to be ineligible for treatment; of these, 40% had the rs12980275 genotype. More than half of the patients with rs12980275 who were ineligible for treatment were excluded because of mental health comorbidities; one-third of these patients had advanced fibrosis. The reason(s) for treatment exclusion resolved in only 8% of patients during a mean 1.5 years of follow-up evaluation. In a well-characterized cohort of patients with HCV, a large proportion (40%) with IL28B polymorphisms associated with response to therapy is ineligible for treatment because of contraindications. One potential role of IL28B genotype analysis could be to identify patients who, although not currently eligible for antiviral treatment, could become so by modifying fixable exclusions to treatment." @default.
• W1987006639 created "2016-06-24" @default.
• W1987006639 creator A5000701800 @default.
• W1987006639 creator A5012682685 @default.
• W1987006639 creator A5027343826 @default.
• W1987006639 creator A5027832933 @default.
• W1987006639 creator A5061206171 @default.
• W1987006639 creator A5061281015 @default.
• W1987006639 creator A5071426386 @default.
• W1987006639 creator A5080574542 @default.
• W1987006639 creator A5086965411 @default.
• W1987006639 date "2014-02-01" @default.
• W1987006639 modified "2023-10-18" @default.
• W1987006639 title "Many Patients With Interleukin 28B Genotypes Associated With Response to Therapy Are Ineligible for Treatment Because of Comorbidities" @default.
• W1987006639 cites W1853325270 @default.
• W1987006639 cites W1974221422 @default.
• W1987006639 cites W1974748046 @default.
• W1987006639 cites W1987972580 @default.
• W1987006639 cites W1989307318 @default.
• W1987006639 cites W1990639092 @default.
• W1987006639 cites W1992690275 @default.
• W1987006639 cites W2010665223 @default.
• W1987006639 cites W2010977999 @default.
• W1987006639 cites W2017013905 @default.
• W1987006639 cites W2017283593 @default.
• W1987006639 cites W2018024307 @default.
• W1987006639 cites W2020257925 @default.
• W1987006639 cites W2026614040 @default.
• W1987006639 cites W2052362906 @default.
• W1987006639 cites W2054245572 @default.
• W1987006639 cites W2063285149 @default.
• W1987006639 cites W2063470257 @default.
• W1987006639 cites W2078251659 @default.
• W1987006639 cites W2086414517 @default.
• W1987006639 cites W2091863240 @default.
• W1987006639 cites W2107433604 @default.
• W1987006639 cites W2111044696 @default.
• W1987006639 cites W2113864802 @default.
• W1987006639 cites W2116848809 @default.
• W1987006639 cites W2137523463 @default.
• W1987006639 doi "https://doi.org/10.1016/j.cgh.2013.08.034" @default.
• W1987006639 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3971998" @default.
• W1987006639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23978349" @default.
• W1987006639 hasPublicationYear "2014" @default.
• W1987006639 type Work @default.
• W1987006639 sameAs 1987006639 @default.
• W1987006639 citedByCount "10" @default.
• W1987006639 countsByYear W19870066392014 @default.
• W1987006639 countsByYear W19870066392015 @default.
• W1987006639 countsByYear W19870066392016 @default.
• W1987006639 countsByYear W19870066392018 @default.
• W1987006639 countsByYear W19870066392020 @default.
• W1987006639 crossrefType "journal-article" @default.
• W1987006639 hasAuthorship W1987006639A5000701800 @default.
• W1987006639 hasAuthorship W1987006639A5012682685 @default.
• W1987006639 hasAuthorship W1987006639A5027343826 @default.
• W1987006639 hasAuthorship W1987006639A5027832933 @default.
• W1987006639 hasAuthorship W1987006639A5061206171 @default.
• W1987006639 hasAuthorship W1987006639A5061281015 @default.
• W1987006639 hasAuthorship W1987006639A5071426386 @default.
• W1987006639 hasAuthorship W1987006639A5080574542 @default.
• W1987006639 hasAuthorship W1987006639A5086965411 @default.
• W1987006639 hasBestOaLocation W19870066391 @default.
• W1987006639 hasConcept C104317684 @default.
• W1987006639 hasConcept C126322002 @default.
• W1987006639 hasConcept C135763542 @default.
• W1987006639 hasConcept C151730666 @default.
• W1987006639 hasConcept C185592680 @default.
• W1987006639 hasConcept C203014093 @default.
• W1987006639 hasConcept C2522874641 @default.
• W1987006639 hasConcept C2776408679 @default.
• W1987006639 hasConcept C2776455275 @default.
• W1987006639 hasConcept C2779159551 @default.
• W1987006639 hasConcept C2779343474 @default.
• W1987006639 hasConcept C2780040827 @default.
• W1987006639 hasConcept C2781399841 @default.
• W1987006639 hasConcept C55493867 @default.
• W1987006639 hasConcept C71924100 @default.
• W1987006639 hasConcept C72563966 @default.
• W1987006639 hasConcept C86803240 @default.
• W1987006639 hasConcept C90924648 @default.
• W1987006639 hasConceptScore W1987006639C104317684 @default.
• W1987006639 hasConceptScore W1987006639C126322002 @default.
• W1987006639 hasConceptScore W1987006639C135763542 @default.
• W1987006639 hasConceptScore W1987006639C151730666 @default.
• W1987006639 hasConceptScore W1987006639C185592680 @default.
• W1987006639 hasConceptScore W1987006639C203014093 @default.
• W1987006639 hasConceptScore W1987006639C2522874641 @default.
• W1987006639 hasConceptScore W1987006639C2776408679 @default.
• W1987006639 hasConceptScore W1987006639C2776455275 @default.
• W1987006639 hasConceptScore W1987006639C2779159551 @default.
• W1987006639 hasConceptScore W1987006639C2779343474 @default.
• W1987006639 hasConceptScore W1987006639C2780040827 @default.
• W1987006639 hasConceptScore W1987006639C2781399841 @default.
• W1987006639 hasConceptScore W1987006639C55493867 @default.
• W1987006639 hasConceptScore W1987006639C71924100 @default.
• W1987006639 hasConceptScore W1987006639C72563966 @default.
• W1987006639 hasConceptScore W1987006639C86803240 @default.

• next